Clarivate, Barcelona, Spain.
Drugs Today (Barc). 2021 Feb;57(2):101-177. doi: 10.1358/dot.2021.57.2.3275929.
2020 will go down in history as a year marked in every respect by the emergence and astonishingly rapid spread of the first major global viral pandemic in a century. It seems like nearly every event or story of the year was influenced in some way by COVID-19, and in that respect, the year ended on a high note with the authorization for emergency use of the first vaccines to prevent SARS-CoV-2 infection and drugs to treat COVID-19. Despite the pandemic's dominance of the 2020 headlines, productivity was at a record high level across all therapeutic areas, as seen by the number of products in this year's review: approximately 50% more than the previous year. Notable achievements include the launch of the first treatment for hepatitis D; regulatory decisions on a suite of biologics for the prevention and treatment of Ebola virus disease, fruit of the 2016-2018 outbreak in the Democratic Republic of Congo; the approval of the first-ever drug to treat Hutchinson-Gilford progeria syndrome, a rare genetic disorder that leads to premature aging; the first treatment developed specifically for thyroid eye disease, also known as Graves' ophthalmopathy; the first nonhormonal, on-demand, vaginal pH-regulating contraceptive; and the first oral allergen immunotherapy for peanut allergy.
2020 年将作为一个世纪以来首次重大全球病毒性大流行出现并惊人迅速传播的一年而载入史册。几乎每一个事件或故事都在某种程度上受到了 COVID-19 的影响，从这方面来说，今年以授权紧急使用预防 SARS-CoV-2 感染的首批疫苗和治疗 COVID-19 的药物而画上了圆满的句号。尽管大流行占据了 2020 年的头条新闻，但所有治疗领域的生产力都达到了创纪录的高水平，从本年度评论中的产品数量就可见一斑：比前一年大约多 50%。值得注意的成就是，推出了首个治疗丁型肝炎的药物；就一系列用于预防和治疗埃博拉病毒病的生物制剂做出了监管决定，这是 2016-2018 年刚果民主共和国疫情的成果；批准了首个治疗亨廷顿舞蹈病的药物，这是一种导致早衰的罕见遗传疾病；首个专门用于甲状腺眼病（也称为格雷夫斯眼病）的治疗方法；首个非激素、按需、阴道 pH 值调节避孕方法；以及首个用于治疗花生过敏的口服过敏原免疫疗法。
